Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) – Equities research analysts at Zacks Research dropped their Q1 2025 EPS estimates for Bio-Rad Laboratories in a report issued on Tuesday, September 5th. Zacks Research analyst R. Anand now expects that the medical research company will earn $5.46 per share for the quarter, down from their prior forecast of $5.47. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $12.93 per share.
BIO has been the topic of several other research reports. StockNews.com assumed coverage on shares of Bio-Rad Laboratories in a research report on Thursday, August 17th. They set a “buy” rating on the stock. Royal Bank of Canada upped their target price on Bio-Rad Laboratories from $522.00 to $524.00 and gave the company an “outperform” rating in a research report on Friday, August 4th. Wells Fargo & Company lowered their price target on Bio-Rad Laboratories from $550.00 to $525.00 and set an “overweight” rating for the company in a research report on Monday, August 7th. Finally, Credit Suisse Group cut their price objective on Bio-Rad Laboratories from $580.00 to $550.00 and set an “outperform” rating on the stock in a report on Friday, August 4th. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $533.00.
Bio-Rad Laboratories Price Performance
Shares of BIO stock opened at $367.88 on Thursday. The firm has a market capitalization of $10.70 billion, a price-to-earnings ratio of -24.51 and a beta of 0.89. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.06 and a current ratio of 5.39. The stock’s 50-day simple moving average is $393.71 and its 200-day simple moving average is $417.63. Bio-Rad Laboratories has a fifty-two week low of $344.63 and a fifty-two week high of $514.25.
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.55 by $0.45. Bio-Rad Laboratories had a positive return on equity of 4.02% and a negative net margin of 15.52%. The firm had revenue of $681.10 million during the quarter, compared to analyst estimates of $697.96 million. During the same quarter in the prior year, the business posted $3.38 EPS. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year.
Institutional Trading of Bio-Rad Laboratories
Several institutional investors have recently bought and sold shares of the business. Heritage Wealth Management LLC grew its stake in Bio-Rad Laboratories by 100.0% in the 4th quarter. Heritage Wealth Management LLC now owns 66 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 33 shares during the period. WASHINGTON TRUST Co boosted its holdings in Bio-Rad Laboratories by 62.5% in the 4th quarter. WASHINGTON TRUST Co now owns 78 shares of the medical research company’s stock worth $33,000 after buying an additional 30 shares during the last quarter. CI Investments Inc. increased its stake in Bio-Rad Laboratories by 50.0% during the 4th quarter. CI Investments Inc. now owns 84 shares of the medical research company’s stock worth $35,000 after buying an additional 28 shares in the last quarter. Desjardins Global Asset Management Inc. acquired a new position in shares of Bio-Rad Laboratories during the first quarter valued at approximately $35,000. Finally, Raleigh Capital Management Inc. boosted its stake in shares of Bio-Rad Laboratories by 138.2% in the first quarter. Raleigh Capital Management Inc. now owns 81 shares of the medical research company’s stock worth $39,000 after acquiring an additional 47 shares during the last quarter. 63.98% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, EVP Michael Crowley sold 500 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $379.39, for a total value of $189,695.00. Following the completion of the transaction, the executive vice president now owns 6,040 shares of the company’s stock, valued at approximately $2,291,515.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Timothy S. Ernst sold 2,350 shares of the stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $395.60, for a total transaction of $929,660.00. Following the sale, the executive vice president now directly owns 2,416 shares of the company’s stock, valued at approximately $955,769.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael Crowley sold 500 shares of Bio-Rad Laboratories stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $379.39, for a total value of $189,695.00. Following the completion of the transaction, the executive vice president now owns 6,040 shares of the company’s stock, valued at approximately $2,291,515.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,150 shares of company stock valued at $1,234,762. Company insiders own 17.06% of the company’s stock.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
Featured Stories
- Five stocks we like better than Bio-Rad Laboratories
- The “How” and “Why” of Investing in 5G Stocks
- These 3 Wood Stocks are about to go on Discount
- How to Invest in Communication Stocks
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
- What Are Dividend Champions? How to Invest in the Champions
- 3 Stocks Awaiting Winter Winds of Opportunity
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
